Clinical Trials Logo

Filter by:
NCT ID: NCT06346392 Recruiting - Gastric Cancer Clinical Trials

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Start date: March 4, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

NCT ID: NCT06346340 Recruiting - Dry Eye Clinical Trials

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

Start date: April 30, 2024
Phase: Phase 4
Study type: Interventional

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy

NCT ID: NCT06346314 Completed - Clinical trials for Pectoralis Minor Length

Is There an Immediate Effect on Pectoralis Minor Length After Performing a Prone Scapular Retraction Exercise

Start date: July 15, 2021
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test normal participants. The main question it aims to answer is: • Do the participant's pectoralis minor muscles change length immediately after performing an exercise that recruits the scapular retractor muscles? Participants will have their pectoralis minor muscle measured, then perform an exercise recruiting the scapular retractor muscles, and then have their pectoralis muscle measured again.

NCT ID: NCT06346262 Recruiting - Epilepsy Clinical Trials

Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care

Start date: March 5, 2024
Phase: Phase 4
Study type: Interventional

This study will be done in two phases. Using stakeholder input (community advisory board (CAB)), the study team will adapt the SMART program to incorporate education and self-management support for use of Rescue Medication (RM) to manage seizure occurrence among Persons With Epilepsy (PWE) who have repetitive seizures. Additional content/support materials, pending input stakeholder might include posters/hand-outs that present information on the use of RM in a way that is engaging and salient to PWE. It is expected that participants will be in Phase 1 for about 3 months and participate in the CAB 2 or 3 times via zoom for 60-90 minutes/meeting. The advisory board will provide input on needed refinement of an adapted version of SMART based on their individual experiences. It is anticipate the total time commitment to be no more than 6 hours over 3 months, spread out over 2-3 meetings with review of materials possible in between meetings. Phase 2: The investigators will use a 6-month prospective trial design to test engagement with and effects of SMART-RM among approximately 35 adult (≥ 18 years) PWE who have repetitive seizures.

NCT ID: NCT06346106 Recruiting - Rett Syndrome Clinical Trials

The Diagnostic Experience of Male Rett Syndrome

Start date: May 24, 2023
Phase:
Study type: Observational

The Diagnostic Experience of Male Rett Syndrome collects information on the lived experiences of parents or caregivers to boys with Rett Syndrome. Key information examined includes the process of getting a male Rett syndrome diagnosis, your son's systems of care, and your priorities for his health needs. Enrolled participants will complete an online survey with questions about having a son with Rett Syndrome. The Diagnostic Experience of Male Rett Syndrome study is available to parents or caregivers to boys (alive or passed) with Rett Syndrome. Compensation is not provided.

NCT ID: NCT06346067 Recruiting - Clinical trials for Advanced or Metastatic NRAS-mutant Melanoma

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Start date: April 29, 2024
Phase: Phase 3
Study type: Interventional

Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).

NCT ID: NCT06345963 Not yet recruiting - Schizophrenia Clinical Trials

Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.

NCT ID: NCT06345872 Recruiting - Chronic Pain Clinical Trials

Improving Sleep and Reducing Opioid Use in Individuals With Chronic Pain

Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this study is to test two behavioral interventions for chronic insomnia in individuals with chronic pain and use prescribed opioid medication to treat their chronic pain.

NCT ID: NCT06345859 Recruiting - Clinical trials for Major Depressive Disorder

Regulation of Affect and Physiology in Depression

RAPID
Start date: March 22, 2024
Phase: Phase 2
Study type: Interventional

Although treatments for depression are effective for many people, not everyone responds to treatment. This lack of treatment response could be due, in part, to the presence of multiple underlying causes of people's depression. This study aims to identify subtypes of depression, based on two factors: how successful people perceive themselves to be at regulating their affect in everyday life; and how much activity in the parasympathetic nervous system increases during moments when people try to regulate. The study involves ambulatory assessment of affect, regulation strategies, and physiological activity in everyday life, in a sample of young adults with remitted major depressive disorder and healthy volunteers. We will study regulation responses in the lab to further determine how subtypes differ in neural, physiological, and behavioral responses. Finally, participants will be randomly assigned to a remote, self-administered biofeedback intervention (vs. control intervention) designed to increase parasympathetic activity and physiological regulation success. While engaging in biofeedback at home for 10 days, participants will simultaneously repeat the ambulatory assessments. This design will allow us to determine the proximal impact of biofeedback on indices of regulation success in everyday life, and whether biofeedback has differential impact on regulation success for different subtypes.

NCT ID: NCT06345794 Recruiting - Healthy Clinical Trials

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

Start date: April 3, 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine.